107
Views
6
CrossRef citations to date
0
Altmetric
Reviews

Isolated limb infusion with melphalan and actinomycin D in melanoma patients: factors predictive of acute regional toxicity

, MD FANZCA FRCA (Nuffield Professor of Anaesthetics) & , MD FRACS FACS (Professor of Melanoma and Surgical Oncology)
Pages 1039-1045 | Published online: 07 Jul 2010

Bibliography

  • Lens MB, Dawes M. Global perspectives of contemporary epidemiological trends of cutaneous malignant melanoma. Br J Dermatol 2004;150:179-85
  • Lingam MK, Byrne DS, Aitchison T, A single centre's 10 year experience with isolated limb perfusion in the treatment of recurrent malignant melanoma of the limb. Eur J Cancer 1996;32A:1668-73
  • McKay A, Byrne DS. Recurrent limb melanoma: treatments other than isolated limb perfusion and infusion. In: Thompson JF, Morton DL, Kroon BB, editors, Textbook of melanoma. Martin Dunitz, London; 2004. p. 443-48
  • Rossi CR, Foletto M, Vecchiato A, Management of cutaneous melanoma: state of the art and trends. Eur J Cancer 1997;33:2302-12
  • Creech O Jr, Krementz ET, Ryan RF, Winblad JN. Chemotherapy of cancer: regional perfusion utilizing an extracorporeal circuit. Ann Surg 1958;148:616-32
  • Thompson JF, de Wilt JH. Isolated limb perfusion in the management of patients with recurrent limb melanoma: an important but limited role. Ann Surg Oncol 2001;8:564-5
  • Karakousis CP, Kanter PM, Lopez R, Modes of regional chemotherapy. J Surg Res 1979;26:134-41
  • Bland KI, Kimura AK, Brenner DE, A phase II study of the efficacy of diamminedichloroplatinum (cisplatin) for the control of locally recurrent and intransit malignant melanoma of the extremities using tourniquet outflow-occlusion techniques. Ann Surg 1989;209:73-80
  • Karakousis CP, Kanter PM, Park HC, Tourniquet infusion versus hyperthermic perfusion. Cancer 1982;49:850-8
  • Thompson JF, Waugh RC, Saw RPM, Kam PC. Isolated limb infusion with melphalan for recurrent limb melanoma: a simple alternative to isolated limb perfusion. Reg Cancer Treat 1994;7:188-92
  • Brady MS, Brown K, Patel A, A phase II trial of isolated limb infusion with melphalan and dactinomycin for regional melanoma and soft tissue sarcoma of the extremity. Ann Surg Oncol 2006;13:1123-9
  • Mian R, Henderson MA, Speakman D, Isolated limb infusion for melanoma: a simple alternative to isolated limb perfusion. Can J Surg 2001;44:189-92
  • Thompson JF, Kam PC, Waugh RC, Harman CR. Isolated limb infusion with cytotoxic agents: a simple alternative to isolated limb perfusion. Semin Surg Oncol 1998;14:238-47
  • Wieberdink J, Benckhuysen C, Braat RP, Dosimetry in isolation perfusion of the limbs by assessment of perfused tissue volume and grading of toxic tissue reactions. Eur J Cancer Clin Oncol 1982;18:905-10
  • Thompson JF, Kam PCA, de Wilt JHW, Lindner P. Isolated limb infusion for melanoma. In: Thompson JF, Morton DL, Kroon BB, editors, Textbook of melanoma. Martin Dunitz, London; 2004. p. 429-37
  • Thompson JF, Kam PCA. Current status of isolated limb infusion with mild hyperthermia for melanoma. Int J Hyperthermia 2008;24:219-25
  • Thompson JF, Ramzan I, Kam PCA, Yau DF. Pharmacokinetics of melphalan during isolated limb infusion for melanoma. Reg Cancer Treat 1996;9:13-16
  • Kam PCA, Thompson JF. Pharmacokinetics of regional therapy: low flow and other techniques for extremity melanoma. Surg Oncol Clin N Am 2008;17:795-804
  • Lindner P, Doubrovsky A, Kam PCA, Prognostic factors after isolated limb infusion for melanoma. Ann Surg Oncol 2002;9:127-36
  • Kroon HM, Moncrieff M, Kam PCA, Outcomes following isolated limb infusion for melanoma. A 14 year experience. Ann Surg Oncol 2008;15:3003-13
  • Kroon HD, Moncrieff M, Kam PCA, Thompson JF. Factors predictive of acute regional toxicity after isolated limb infusion with melphalan and actinomycin D in melanoma patients. Ann Surg Oncol 2009;16:1184-92
  • Beasley GM, Caudie A, Peterson RP, A multi-institutional experience of isolated limb infusion: defining response and toxicity in the US. J Am Coll Surg 2009;208:706-15
  • Beasley GM, Peterson RP, Yoo J, Isolated limb infusion for in-transit malignant melanoma of the extremity: a well tolerated but less effective alternative to hyperthermic isolated limb perfusion. Ann Surg Oncol 2008;15:2195-205
  • Santillan AA, Delman KA, Beasley GM, Predictive factors of regional toxicity and serum creatine phosphokinase levels after isolated limb infusion for melanoma: a multi-institutional analysis. Ann Surg Oncol 2009;16:2570-8
  • Cavaliere R, Ciocatto EC, Giovanella BC, Selective heat sensitivity of cancer cells. Biochemical and clinical studies. Cancer 1967;20:1351-81
  • Siemann DW, Chapman M, Beikirch A. Effects of oxygenation and pH on tumour cell response to alkylating chemotherapy. Int J Radiat Oncol Biol Phys 1991;20:287-9
  • Skarsgard LD, Skwarchuk MW, Vinczan A, The cytotoxicity of melphalan and its relationship to pH, hypoxia and drug uptake. Anticancer Res 1995;15:219-23
  • Bonenkamp JJ, Thompson JF, de Wilt JH, Isolated limb infusion with fotemustine after dacarbazine chemosensitisation for inoperable loco-regional. Eur J Surg Oncol 2004;30:1107-12
  • Wu ZY, Smithers BM, Anderson C, Can tissue drug concentrations be monitored by microdialysis during and after isolated limb perfusion for melanoma treatment? Melanoma Res 2000;10:47-54
  • Thompson JF, Siebert GA, Anissimov YG, Microdialysis and response during regional chemotherapy by isolated limb infusion of melphalan for limb malignancies. Br J Cancer 2001;85:157-65

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.